Around 8% of the population in America experiences sleep bruxism - a disorder characterized by teeth grinding and jaw clenching that leads to headaches, the wearing
down of teeth, and jaw pain - to mention just a few effects. A new market research report called COVID-19 Impact on Sleeping Bruxism Treatment Market Overview and Forecast 2020 to 2026 has found that the current health crisis has led to a spike in bruxism. The report forecasts a big rise in the need for treatment of the effects of bruxism owing to currently high levels of stress across the globe.
Why Is Bruxism On The Rise?
It is a stressful time in many ways, and this increases the likelihood of teeth grinding and jaw clenching at night. A study published in the journal Head & Face Medicine showed that nightly gnashing of teeth was especially prevalent among those who tried to cope with stress by escaping from difficult situations. Bruxism can lead to everything from tooth sensitivity to pain in the muscles of the jaw responsible for chewing. While there are many exercises to soothe tight jaw muscles, this is just one approach that should be considered. Because bruxism can actually lead to tooth loss, it should be taken seriously, and if stress is the cause, then this separate issue should also be tackled proactively.
Dr. Kelleher[/caption]
Cassandra M. Kelleher, MD, FACS
Surgical Director, Fetal Care Program
Surgical Director, NICU
Quality and Safety Chair, Pediatric Surgery
MGH eCare Clinical Informaticist
Pediatric Surgery
MassGeneral Hospital for Children
Boston, MA
MedicalResearch.com: What is the background for this study?
Response: Only about one in five surgeons practicing in U.S. is female. Unemployment is virtually nonexistent among surgeons, but many female surgeons, as well as professional women in other fields, experience underemployment—the underuse of skills—according to the Federal Reserve Bank. Women in surgery talk among themselves about how they may be perceived as less confident or competent, and for those reasons they may have less opportunity to do exciting and challenging cases. We wondered if this was true, and if so, why?
Dr. Rosano[/caption]
Caterina Rosano, M.D., M.P.H.
Professor of Epidemiology
University of Pittsburgh Graduate School of Public Health
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Most people think about dopamine’s role in mobility in the context of Parkinson’s disease, but not in normal aging. We were curious to see if a genetic predisposition to produce more or less dopamine was related to mobility in individuals who had some level of frailty, yet did not have dementia, parkinsonism or any other neurological condition.
While several genetic elements control dopamine signaling, my team and I focused on a gene called COMT, which breaks down dopamine to control its levels within the brain. We also considered the frailty status of participants, which is a common consequence of aging marked by a decline in physiological function, poor adjustment to stressors and a susceptibility toward adverse health outcomes. We suspected that frail participants could be particularly vulnerable to COMT-driven differences in dopamine levels.
We examined this gene in more than 500 adults above the age of 65 in Pennsylvania, North Carolina, California and Maryland, excluding any participants taking dopamine-related medications or diagnosed with Parkinson’s disease. We then looked for potential links between genotype, frailty and speed.
We discovered that frail participants with a high-dopamine COMT genotype had a 10% faster walking speed compared with participants with the low-dopamine COMT genotype.
Dr. Kaufmann[/caption]
Christopher Kaufmann, PhD
Co-first author of the study and assistant professor
Division of Geriatrics and Gerontology in the Department of Medicine
UC San Diego
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We examined cannabis use by older patients seen in our geriatrics clinic at the University of California San Diego. We surveyed patients who came to our clinic for routine care, and found that 15% of those surveyed had used cannabis within the past 3 years. Half of users reported using cannabis regularly and most used for medical purposes. The most common targeted conditions were pain, problems sleeping, and anxiety, and patients found cannabis to be helpful in treating these conditions. We also found that 61% had initiated cannabis use after age 60, and these new users engaged in less risky consumption practices than current users who also used earlier in life.
Jim Gleason, National President of Transplant Recipients International Organization (TRIO), discusses what organ transplant patients are experiencing during the pandemic, and some tips they ought to consider to help ease some of the burden.
Mr. Gleason also discusses his role in the development of the recently released AlloCare app is in the AppStore -- https://apps.apple.com/us/app/allocare-transplant-health/id1497962881?ign-mpt=uo%3D2 – to help post-transplant recipients navigate their day-to-day health.
MedicalResearch.com: Would you describe your journey with organ transplantation?
Mr. Gleason: I was diagnosed with heart failure at the age of 49, 2 years later listed with Penn Medicine in Philadelphia in September of 1994, and received my donor heart on October 19, 1994.
After I received my transplant, I was home from the hospital 7 days later and able to return to work in 3 months as a computer manager with Unisys Corp in Blue Bell, PA, where I worked for the next dozen years before my retirement.
Once retired, I dedicated my time to raising awareness of the need for organ donation and the success of transplants ever since. Today, 26 active and fulfilled years with my new heart and gift of life, I am able to live life to its fullest at age 77. I am now also coincidentally married to an organ donor of 15 years, who donated her 13-year-old son’s organs when he was hit by a car on his bike back in 1997.
Dr. Leonie Kausel[/caption]
Leonie Margarita Kausel, PhD
Postdoctoral Researcher
Development University
Santiago, Chile
MedicalResearch.com: What is the background for this study?
Response: As a violin teacher, I observed the positive impact on many levels that musical training has on children and as a scientist (Biochemist), I was intrigued to be able to show this with data. I thought this was very important, because in my experience childhood music education can give you so much joy and important skills for life, but it is often not considered to be important in educational settings. After attending a seminar on education and neuroscience, I discovered that this discipline could allow me to investigate this in a scientific manner. This inspired me to enter the Neuroscience PhD program at the Pontificia Universidad Católica de Chile where I was lucky to work with Dr. Francisco Aboitiz, who has vast experience in attention research (ADHD) and is an international expert in language and evolution. At that time Dr. Mary Elizabeth Sutherland was making her postdoc at the lab, and she had worked with Dr. Robert Zatorre, one of the leading researchers in music and the brain. Also, I was lucky to work with Dr. Francisco Zamorano, a pioneer of fMRI research in Chile. So together we designed the research. :) Also, I am very grateful that I could make a research stay at the Lab of Dr. Gottfried Schalug, who is also a pioneer in the research of music and the brain, and who inspired me to do this research since he wrote the first papers that I read about this subject.
Dr. Herbst[/caption]
Roy S. Herbst, M.D., Ph.D.
Ensign Professor of Medicine (Medical Oncology) and
Professor of Pharmacology
Chief of Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director for Translational Research
Yale Cancer Center
MedicalResearch.com: What is the background for this study? How does osimertinib differ from prior versions of EGFR-TKI Inhibitors?
o ADAURA is a randomized, double-blinded, global and placebo-controlled Phase III trial in the adjuvant treatment of 682 patients with Stage IB, II, and IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with osimertinib 80 mg once-daily oral tablets or placebo for three years or until disease recurrence. The primary endpoint is disease free survival (DFS) in Stage II and IIIA patients, and a key secondary endpoint is DFS in Stage IB, II and IIIA patients. Osimertinib is not currently approved in the adjuvant setting in any country.
o Osimertinib is a third-generation, irreversible EGFR-TKI with clinical activity against central nervous system metastases. The results of the Phase III ADAURA trial of osimertinib demonstrate for the first time in a global trial that an EGFR inhibitor can change the course of early-stage EGFR-mutated lung cancer for patients.
o ADAURA results were first presented in May during the American Society of Clinical Oncology ASCO20 Virtual Scientific Program.
Prof. Wisløff[/caption]
Ulrik Wisløff
Professor and Head of CERG and K.G. Jebsen Centre for Exercise in Medicine
of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences
NTNU-Norwegian University of Science and Technology
Trondheim, Norway
MedicalResearch.com: What is the background for this study?
Response: The Generation 100 study followed more than 1500 women and men in their 70s for five years. The aim was to find out if exercise gives older adults a longer and healthier life, and we also compare the effect of moderate and high-intensity exercise.
MedicalResearch.com: What are the main findings?
Response: Overall survival was high in all three groups, compared to what’s expected in this age group. There was a clear trend towards greater survival in the high-intensity compared to the moderate intensity exercise group. High-intensity interval training also had the greatest effect on cardiorespiratory fitness and health-related quality of life.
Response: The background for this study involves the associations of household rules and parental awareness with youth tobacco use using data from the Population Assessment Tobacco and Health Study. Health concerns regarding non-cigarette tobacco products, specifically e-cigarettes, have been on the rise. We wanted to explore whether parents are up to date with the trends of popular tobacco products today and what role they may play in youth tobacco cessation and prevention.
The main findings of the study revealed that parents less often suspected their children’s tobacco use if their children reported using only e-cigarettes, and other non-cigarette tobacco products, when compared with cigarettes. Additionally, we found that youth who agreed with their parents that their home has strict rules for tobacco use were less likely to initiate of tobacco use compared to youth who had different understanding of the rules from their parents or youth from households with more permissive household rules.
Donna R. Cryer, JD[/caption]
Donna R. Cryer, JD
President & CEO of the Global Liver Institute
MedicalResearch.com: What is the background for this announcement? What is the mission of the GLI?
Response: Global Liver Institute 's (GLI) mission is to improve the impact of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver diseases. Our vision is for liver health to take its proper place on the global public health agenda consistent with its prevalence and impact. One of the ways we seek to fulfill that mission is through a #OctoberIs4Livers worldwide awareness campaign for the fight against liver cancer, reinforcing October as liver disease and liver cancer awareness month. Not only are we seeing a continuous rise of prevalence of liver cancers, but survival rates for liver cancers are also some of the lowest of any cancer.
Even more concerning is that the startling truth about the rise of liver cancer rates began before the COVID-19 pandemic. With the added burden of COVID-19, patients directly at risk from the virus may be diagnosed at a later stage due to delayed screening, and are getting sicker due to limitations on access to care during this pandemic. GLI is appealing to the US Congress to act now to secure the health and well-being of people living with liver disease and liver cancers during COVID-19. Funding is crucial to ensure federal agencies can restart and continue medical research, implement targeted prevention, and support awareness efforts for those impacted by liver disease as they are at increased risk for severe illness from COVID-19. [1]
Padma Sundar[/caption]
MedicalResearch.com Interview with:
Padma Sundar, Senior Vice President of Commercial , OncocyteTM
oncocyte.com
MedicalResearch.com: What is the background for this announcement? How common is Stage I-IIA non-squamous NSCLC?
DetermaRxTM is a treatment stratification test to identify patients with Stage I-IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy.
Dr. Senior[/caption]
Brent A. Senior, MD, FACS, FARS
Professor of Otolaryngology/Neurosurgery
Vice Chairman for Clinical Affairs
Nathaniel and Sheila Harris Distinguished Professor
Chief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery
Department of Otolaryngology-Head and Neck Surgery
University of North Carolina at Chapel Hill
Chapel Hill, NC
MedicalResearch.com: What is the background for this study? How common is the problem of chronic rhinosinusitis with nasal polyps?
Response: Chronic rhinosinusitis (CRS) is a very common illness in the United States and around the world, estimated to impact 2-14% of the US population. Chronic rhinosinusitis with polyps is a particularly challenging form of the disease marked by significant impact on quality of life, and being challenging to treat with significant recurrences of symptoms despite standard medical and surgical treatment.
Inhaled intranasal steroids are standard therapy for patients with CRS including those with nasal polyps. However, many patients continue to have significant nasal symptoms despite treatment with these medications. This study was designed to answer the question of whether patients who had been receiving treatment with inhaled intranasal steroids and failed were improved by using EDS-FLU. Results were obtained by pooling data from two previous studies of the use of EDS-FLU in patients with CRS, called Navigate 1 and 2.
Dr. Nagata, MD[/caption]
Jason Nagata, MD, MSc
Assistant Professor of Pediatrics
University of California, San Francisco
San Francisco, California, USA
MedicalResearch.com: What is the background for this study?
Response: During the COVID-19 pandemic, food insecurity is expected to rise given economic uncertainty and job losses. Vulnerable and marginalized populations are disproportionately affected by both COVID-19 and food insecurity.
MedicalResearch.com: What are the main findings?
Response: In this perspective, we argue that food insecurity and COVID-19 can exacerbate one another via bidirectional links. Experiencing food insecurity can lead to nutritional deficiencies and weakened host defenses, increasing susceptibility to COVID-19 infection. Food insecurity is also associated with chronic medical conditions which may lead to a higher risk of severe COVID-19 illness.
Conversely, people with COVID-19 may not be able to work, generate income, or procure food while quarantined, which may worsen food insecurity.
Dr. Lanza[/caption]
Isabella Lanza, PhD
Associate Professor of Human Development
California State University, Long Beach
MedicalResearch.com: What is the background for this study? What are the main findings? Response: This is the first study to examine both nicotine vaping and cannabis vaping trajectories across adolescence and young adulthood, which allowed us to assess whether poly-substance vaping is common among adolescents and young adults. Poly-substance vaping (nicotine and cannabis vaping) was reported among a significant proportion of participants in the study (25% were identified as poly-substance vapers). For those that either escalated to frequent nicotine vaping use in adolescence or initiated frequent nicotine vaping use in young adulthood, the probability of engaging in cannabis vaping was very high (85%+).
Nathan B. Warren[/caption]
Nathan Warren is a Ph.D. candidate in marketing at the University of Oregon. His research examines how people respond when social norms, such as masculinity norms, are disrupted by social change. He hopes that his research can empower people who are struggling to adapt to changing norms to live healthier, happier, and more productive lives. For more information on his research, please visit: www.nathanwarrenresearch.com
[caption id="attachment_55579" align="alignleft" width="150"]
Dr. Troy Campbell[/caption]
Dr. Troy Campbell is a behavioral scientist (PhD, Duke University), former marketing professor (University of Oregon), former art, film, and psychology scholar (UC Irvine), professional designer and researcher (Netflix Insights, Disney Imagineering, UnitedHealth) and currently chief scientist at On Your Feet. Troy believes everything can be awesome when you start with the right science and follow with the right creative process, and he hopes his professional services or public guides can help his clients make something awesome and impactful. For more information on Troy Campbell, please visit: www.troy-campbell.com
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: In the United States, the average American sleeps less than the minimum seven hours of sleep per night recommended by the Center for Disease Control, and nearly half of Americans report negative consequences from insufficient sleep. This problem appears to be especially prevalent in men, who report getting significantly less sleep, on average, than women.
A cultural complication is the notion that getting less than the recommended amount of sleep signals something positive about an individual. For example, US President Donald Trump has boasted about getting less than four hours of sleep per night and regularly derogates his political opponent Joe Biden as “Sleepy Joe.”
"The Sleep-Deprived Masculinity Stereotype," a new paper in the Journal of the Association for Consumer Research, examines a possible stereotype connecting sleep and masculinity along with its underlying mechanisms and its social implications.
Authors Nathan B. Warren and Troy H. Campbell conducted 12 experiments involving 2,564 American participants to demonstrate that a sleep-deprived masculinity stereotype exists. In one experiment, participants were asked to imagine seeing a man shopping for a bed. Then, a salesperson asked the man, “How much do you normally sleep?” The results found that the mean masculinity rating for participants in the lots of sleep condition was significantly lower than the mean masculinity rating for participants in the little sleep condition.
In another experiment, participants were asked to ascribe different attributes to a male character, assigned to either a “very masculine and manly” man or a “not very masculine and not very manly” man. Participants in the masculine condition described their character sleeping 33 minutes less sleep per night than the characters described in the not masculine condition. A final experiment showed that participants who imagined stating they sleep more than average felt significantly less masculine than participants who imagined stating they sleep less than average.
Collectively, the experiments found that men who sleep less are seen as more masculine and more positively judged by society. The same patterns were not consistently observed for perceptions of women.
Dr. Bandi[/caption]
Priti Bandi PhD
Principal Scientist, Risk Factors Surveillance Research
American Cancer Society, Inc.
Atlanta, GA 30303
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Trends in e-cigarette prevalence and population count of users according to cigarette smoking histories are unknown. These data are needed to inform public health actions against a rapidly changing U.S. e-cigarette market.
Dr. Anderson[/caption]
Evan J. Anderson, MD
Associate Professor of Medicine and Pediatrics
Emory University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: Older adults have suffered a disproportionate number of the hospitalizations and deaths due to COVID-19. A vaccine is clearly needed for older adults. For a number of vaccines, the immune response and efficacy of vaccines decreases with increasing age. A prime example would be influenza and the need for high dose influenza vaccine in the elderly. We had previously conducted a Phase I study in 18 – 55 year old adults of mRNA-1273 vaccine – published in NEJM 2020 with Lisa Jackson as the lead author. This phase I study was expanded to include older adults in 2 separate cohorts (56 – 70, >70 years of age) and 2 different doses.
Dr. Moline[/caption]
Margaret Moline, PhD
Executive Director, Neurology Business Group, Eisai, Inc
Lemborexant International Program Lead and Global Medical Lead
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Driskell[/caption]
Ryan R. Driskell Ph.D.
Assistant Professor
School of Molecular Biosciences
Center for Reproductive Biology
Washington State University
Pullman, WA. 99164
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Scars a serious health concern when they cover large areas of the body. Understanding how to functionally regenerate skin can improve the quality of life for individuals with large scars.
Importantly, our study is proof of concept, in that we identified a genetic factor that allows adult skin to repair itself like the skin of a newborn babe. The discovery has implications for better skin wound treatment as well as preventing some of the aging process in skin.
Dr. Wenquan Zou[/caption]
Wenquan Zou, MD/PhD, Professor
Department of Pathology
Associate Director
National Prion Disease Pathology Surveillance Center
Case Western Reserve University School of Medicine
Cleveland, Ohio 44106
MedicalResearch.com: What is the background for this study?
Response: Parkinson’s disease (PD) is the second most common age-related neurodegenerative disorder. It is characterized by the accumulation of pathologically misfolded α-synuclein (αSynP) aggregates in the brain. Currently, a definite diagnosis relies on the detection of αSynP-containing Lewy bodies in the brain of PD patients. Development of a reliable and sensitive assay for αSynP in easily accessible peripheral tissue specimens is critical for early or differential diagnosis, determination of disease severity, and evaluation of therapeutic efficacy in clinical trials. Previous studies have revealed that the pathologically phosphorylated α-synuclein is detectable with traditional immunohistochemistry (IHC) and immunofluorescence (IF) microscopy but the sensitivity with IHC/IF is highly variable and inconsistent.
Also the prion-like aggregation seeding activity of αSynP is detected in cerebrospinal fluid (CSF) of Parkinson’s disease patients with highly sensitive real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification assays (PMCA). But the lumbar puncture to collect CSF is more invasive compared to skin punch biopsy.
Dr. Garg[/caption]
Dr. Madhur Garg, MD MBA
Clinical director, Radiation Oncology
Montefiore Health System and Professor
Departments of Otorhinolaryngology - Head & Neck Surgery - and Urology
Albert Einstein College of Medicine
MedicalResearch.com: What is the background for this study?
Response: The Bronx was hit particularly hard with Covid-19 - making up one of the highest per capita cases and deaths in the country. Montefiore Health System and Albert Einstein College of Medicine, care for a large population of ethnic minorities (non-Hispanic Black and Hispanic individuals make up 65% of our patient population).
Dr. Hussain[/caption]
MedicalResearch.com Interview with:
Maha Hussain, MD, FACP, FASCO
Genevieve Teuton Professor of MedicineDivision of Hem/Onc
Deputy Director
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
MedicalResearch.com: What is the background for this study?
Response: PROfound is an open-label international Phase III clinical trial which evaluated the efficacy and safety of Olaparib (Lynparza) versus enzalumatide or abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior treatment with NHA treatments (abiraterone and prednisone or enzalutamide) and have a qualifying tumor mutation in BRCA1/2, ATM or one of the other genes involved in the HRR pathway.
The trial design included 2 cohorts; Cohort A included patients with BRCA1,2 or ATM and Cohort 2 included patients with 12 other HRR genes.
Dr. Pollard[/caption]
Michael S. Pollard, Ph.D.
Professor, Pardee RAND Graduate School
Senior Sociologist
RAND Corporation
Santa Monica, CA 90407-2138
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There are ample anecdotal jokes and stories about increased alcohol use during COVID-19 and stay-at-home orders. Our study provides robust longitudinal evidence that people drank more frequently, and for women in particular, more heavily, and with more negative consequences, during the initial stages of COVID-19 compared to their own behaviors from a year earlier (May/June 2020 compared to May/June 2019). Women’s alcohol consumption was most significantly changed, with a 17% increase in number of days drinking, and a 41% increase in days of binge drinking (when they had four or more drinks in a couple of hours). This means that, nationally, one in five women drank heavily one more day a month than the same time in 2019, on average. Women also reported a 39% increase in alcohol-related problems, such as “I took foolish risks” or “I failed to do what was expected of me” because of drinking alcohol.
Prof. Medland[/caption]
Professor Sarah Medland
Coordinator of the Mental Health Research Program and Group Leader Psychiatric Genetics
QIMR Berghofer Medical Research Institute
MedicalResearch.com: What is the background for this study?
Response: This large collaborative project involving participants and researchers from around the world which has been underway for about 10 years. The aim was to try and identify genetic variants that influence handedness with the goal of increasing our knowledge about the way lateralization develops in behaviour and in the brain.
In this project we were able to bring together results from cohort studies conducted by academic collaborators, the UK Biobank and 23andMe yielding a total sample size of over 1.7 million participants. Working with Professor David Evans the co-senior author of the paper (University of Queensland) and Dr Gabriel Cuellar-Partida the first author of the paper (formally UQ now at 23andMe) and the other researchers who worked on the project we meta-analysed the genome-wide association analysis results from the cohorts and were able to identify 41 genetic variants that influence left-handedness and 7 that influence ambidextrousness.
The Stars Know